Literature DB >> 23034966

Effect of tumor burden and subsequent surgical resection on skeletal muscle mass and protein turnover in colorectal cancer patients.

John P Williams1, Bethan E Phillips, Kenneth Smith, Philip J Atherton, Debbie Rankin, Anna L Selby, Sarah Liptrot, Jonathan Lund, Mike Larvin, Michael J Rennie.   

Abstract

BACKGROUND: Cachexia is a consequence of tumor burden caused by ill-defined catabolic alterations in muscle protein turnover.
OBJECTIVE: We aimed to explore the effect of tumor burden and resection on muscle protein turnover in patients with nonmetastatic colorectal cancer (CRC), which is a surgically curable tumor that induces cachexia.
DESIGN: We recruited the following 2 groups: patients with CRC [n = 13; mean ± SEM age: 66 ± 3 y; BMI (in kg/m(2)): 27.6 ± 1.1] and matched healthy controls (n = 8; age: 71 ± 2 y; BMI: 26.2 ± 1). Control subjects underwent a single study, whereas CRC patients were studied twice before and ~6 wk after surgical resection to assess muscle protein synthesis (MPS), muscle protein breakdown (MPB), and muscle mass by using dual-energy X-ray absorptiometry.
RESULTS: Leg muscle mass was lower in CRC patients than in control subjects (6290 ± 456 compared with 7839 ± 617 g; P < 0.05) and had an additional decline after surgery (5840 ± 456 g; P < 0.001). Although postabsorptive MPS was unaffected, catabolic changes with tumor burden included the complete blunting of postprandial MPS (0.038 ± 0.004%/h in the CRC group compared with 0.065 ± 0.006%/h in the control group; P < 0.01) and a trend toward increased MPB under postabsorptive conditions (P = 0.09). Although surgical resection exacerbated muscle atrophy (-7.2%), catabolic changes in protein metabolism had normalized 6 wk after surgery. The recovery in postprandial MPS after surgery was inversely related to the degree of muscle atrophy (r = 0.65, P < 0.01).
CONCLUSIONS: CRC patients display reduced postprandial MPS and a trend toward increased MPB, and tumor resection reverses these derangements. With no effective treatment of cancer cachexia, future therapies directed at preserving muscle mass should concentrate on alleviating proteolysis and enhancing anabolic responses to nutrition before surgery while augmenting muscle anabolism after resection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034966     DOI: 10.3945/ajcn.112.045708

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  38 in total

Review 1.  Role of interleukin-6 in cachexia: therapeutic implications.

Authors:  Aditi A Narsale; James A Carson
Journal:  Curr Opin Support Palliat Care       Date:  2014-12       Impact factor: 2.302

Review 2.  Ribosome biogenesis: emerging evidence for a central role in the regulation of skeletal muscle mass.

Authors:  Thomas Chaillou; Tyler J Kirby; John J McCarthy
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

3.  Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma.

Authors:  Toshihiro Matsukawa; Keito Suto; Minoru Kanaya; Koh Izumiyama; Koichiro Minauchi; Shota Yoshida; Hisashi Oda; Takuto Miyagishima; Akio Mori; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
Journal:  Ann Hematol       Date:  2020-09-24       Impact factor: 3.673

4.  Cachexia Disrupts Diurnal Regulation of Activity, Feeding, and Muscle mTORC1 in Mice.

Authors:  Brittany R Counts; Justin P Hardee; Dennis K Fix; Brandon N VanderVeen; Ryan N Montalvo; James A Carson
Journal:  Med Sci Sports Exerc       Date:  2019-10-23       Impact factor: 5.411

5.  Detection of Pancreatic Cancer-Induced Cachexia Using a Fluorescent Myoblast Reporter System and Analysis of Metabolite Abundance.

Authors:  Paul T Winnard; Santosh K Bharti; Marie-France Penet; Radharani Marik; Yelena Mironchik; Flonne Wildes; Anirban Maitra; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

6.  Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

Authors:  Philippe Atlan; Mohamed Amine Bayar; Emilie Lanoy; Benjamin Besse; David Planchard; Jordy Ramon; Bruno Raynard; Sami Antoun
Journal:  Support Care Cancer       Date:  2017-06-08       Impact factor: 3.603

Review 7.  Molecular mechanism of sarcopenia and cachexia: recent research advances.

Authors:  Kunihiro Sakuma; Wataru Aoi; Akihiko Yamaguchi
Journal:  Pflugers Arch       Date:  2017-01-19       Impact factor: 3.657

8.  Incidence and risk factor analysis for sarcopenia in patients with cancer.

Authors:  Guoxing Zhang; Xiujiang Li; Changping Sui; Hui Zhao; Jihong Zhao; Yue Hou; Yujun DU
Journal:  Oncol Lett       Date:  2015-12-09       Impact factor: 2.967

Review 9.  Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.

Authors:  Erin E Talbert; Denis C Guttridge
Journal:  Semin Cell Dev Biol       Date:  2015-09-16       Impact factor: 7.727

10.  Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.

Authors:  James P White; Melissa J Puppa; Song Gao; Shuichi Sato; Stephen L Welle; James A Carson
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-26       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.